The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Global disparities in access to novel multiple myeloma therapies
Heinz Ludwig, MD, Wilhelminen Cancer Research Institute, Vienna, Austria, discusses disparities in access to novel therapies for patients with multiple myeloma across Europe and globally. He highlights the relationship between national economic resources and access to effective treatments, emphasizing the substantial challenges faced by patients in lower-income countries. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
